CANTON, Mich. (September 22, 2021) – MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced the release of SmartStart™ Tech-Enabled Templates to reduce time and effort in the document content creation process while increasing the quality of deliverables.
SmartStart™ Templates apply structured authoring rules to the authoring process and include tech-enabled templates for protocols, statistical analysis plans (SAPs), and clinical study reports (CSRs). These templates were developed to improve consistency, time-savings, and quality while allowing for the reuse of data across deliverables, such as protocol to protocol, protocol to CSR, protocol to SAP, CSR to CSR, and SAP to SAP.
Key features of SmartStart™ templates are proven to reduce human errors by:
- Automatically sharing reusable content within and across protocols, SAPs, and CSRs
- Reusable content in the body of the protocol and CSR will automatically update in the synopsis
- Reusable content can be imported between documents
- Increasing quality and reduction of authoring and QC effort
- Efficiently presenting reusable content across products, programs, and therapeutic areas
- Decreasing review times, allowing reviewers to focus on newly-added content
“A goal of the organization is to accelerate the development of new therapies,” said Audelia Munguia, Director of Safety Risk Management at MMS. “The innovative technology of our SmartStart™ templates will greatly reduce the time and effort needed when writing deliverables and bring therapies to patients quicker.”
Sponsors who use SmartStart™ Templates will experience increased consistency and efficiencies for internal teams, sites, regulators, investigational review boards (IRB), and patients, as well as in downstream documents as previously completed protocols can be transferred into SmartStart™ Templates.
Learn more about MMS technologies here.
About MMS Holdings
MMS is an award-winning, data-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating, and the company was named Most Outstanding CRO in the 2019 Biotechnology Awards and Best Global CRO in the 2018 International Life Sciences Awards. For more information, visit www.mmsholdings.com or follow MMS on LinkedIn.
Media Contact
Avery Zimmerman
Media@mmsholdings.com
